Therapeutic strategies, consequences and prospects of glucagon-like peptide-1 agonists

QR Code

Therapeutic strategies, consequences and prospects of glucagon-like peptide-1 agonists

Social media shapes aesthetic trends in modern society significantly. Changes in requirements of aesthetic and plastic surgery based on these social trends have been repeatedly demonstrated. Social trends shape not only the requirements for appearance but also affect the pharmaceutical choice of the...

Full description

Saved in:

Bibliographic Details
Main Author:	N.M. Bobok
Format:	Article
Language:	English
Published:	Zaslavsky O.Yu. 2025-05-01
Series:	Mìžnarodnij Endokrinologìčnij Žurnal
Subjects:	glucagon-like peptide-1 receptor agonists biomarker of cardiometabolic complications of type 2 diabetes mellitus obesity treatment review
Online Access:	https://iej.zaslavsky.com.ua/index.php/journal/article/view/1544
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review
by: Shakila Meshkat, et al.
Published: (2025-07-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Association of Glucagon‐Like Peptide Agonist Therapy With Dietary Patterns in a Cross‐Sectional Cohort
by: Eric J. Brandt, et al.
Published: (2025-06-01)

Research progress on mechanisms of glucagon-like peptide-1 receptor agonists in diabetic retinopathy
by: HE Cuihuan, SHI Derong, SUN Dandan, LI Yurui, XIA Guanghao
Published: (2025-02-01)

Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database
by: Chao Tao, et al.
Published: (2025-07-01)

Diet quality and nutrient distribution while using glucagon-like-peptide-1 receptor agonist: A secondary cross-sectional analysis
by: Brittany V.B. Johnson, et al.
Published: (2025-12-01)

Investigation of potential relationship between glucagon-like peptide 1 receptor agonists with suicide/self-injury: disproportionality analysis using WHO-VigiBase
by: Ye Young Kim, et al.
Published: (2024-12-01)

The role of glucagon-like peptide-1 receptor agonists in the correction of immune and metabolic disorders in women with reproductive dysfunction
by: N. D. Kozhukhov, et al.
Published: (2020-04-01)

The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
by: Areesha Moiz, et al.
Published: (2025-08-01)

Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment?
by: Dan Kaufmann, et al.
Published: (2025-06-01)

Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight
by: Claire H. Feetham, et al.
Published: (2025-09-01)

Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
by: Dariush Mozaffarian, et al.
Published: (2025-09-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

Emerging concepts in obesity management: focus on glucagon receptor agonist combinations
by: Sarah L Anderson
Published: (2025-07-01)

Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact
by: Zhixuan Xie, et al.
Published: (2025-07-01)

Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational
by: Olga P. Kovtun, et al.
Published: (2025-05-01)

Glucagon and Glucose Availability Influence Metabolic Heterogeneity and Malignancy in Pancreatic Neuroendocrine Tumour (pNET) Cells: Novel Routes for Therapeutic Targeting
by: Bárbara Ferreira, et al.
Published: (2025-06-01)

Multiagonists of the “incretin axis” as a promising tool for managing cardiometabolic risk in visceral obesity
by: M. A. Druzhilov, et al.
Published: (2022-05-01)

The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome: A Narrative Review
by: Kamil Turlej, et al.
Published: (2025-07-01)

GLP-1 and Its Role in Glycogen Production: A Narrative Review
by: Joseph Lotosky, et al.
Published: (2025-06-01)

Comparison of New‐Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium–Glucose Cotransporter‐2 Inhibitors, Dipeptidyl Peptidase‐4 Inhibitors, or Glucagon‐Like Peptide‐1 Agonists: A Population‐Based Cohort Study
by: Oscar Hou‐In Chou, et al.
Published: (2025-06-01)

The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review
by: Michael Nunns, et al.
Published: (2025-06-01)

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
by: Lampros Chrysavgis, et al.
Published: (2025-06-01)

Comparative analysis of pharmacokinetic parameters, bioequivalence, safety, tolerability and immunogenicity of semaglutide-based drug for the treatment of obesity
by: A. S. Ametov, et al.
Published: (2025-03-01)

Efficacy of liraglutide in patients with metabolic-associated steatotic liver disease in type 2 diabetes mellitus
by: Yu.M. Stepanov, et al.
Published: (2025-06-01)

A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide
by: Laura Patton, et al.
Published: (2025-07-01)

The main directions and prospects in polycystic ovary syndrome treatment
by: A. N. Useinova, et al.
Published: (2021-12-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated by Diabetes: Pathophysiology and Emerging Therapies
by: Hisanori Goto, et al.
Published: (2025-07-01)

Addressing weight loss management in obese gout patients: guidance for future trials
by: Robin Christensen, et al.
Published: (2024-11-01)

Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
by: Bisma Fatima Hammad, et al.
Published: (2025-07-01)

GLP-1R as a potential link between diabetes and Alzheimer’s disease
by: Shujun Li, et al.
Published: (2025-07-01)

Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide
by: A. S. Ametov, et al.
Published: (2023-11-01)

Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants
by: Amirah Alhowiti, et al.
Published: (2025-07-01)

Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
by: Jung A Kim, et al.
Published: (2025-07-01)

Multiomics insight into the role of glucagon‐like peptide‐1 receptor agonists in heart failure
by: Yuhang Tao, et al.
Published: (2025-08-01)

Gut Hormones and Inflammatory Bowel Disease
by: Jonathan Weng, et al.
Published: (2025-07-01)

Granuloma annulare after starting semaglutide
by: Tajena Jones, BS, et al.
Published: (2025-08-01)

Pharmacologic Disruption: How Emerging Weight Loss Therapies Are Challenging Bariatric Surgery Guidelines
by: Safi G. Alqatari, et al.
Published: (2025-07-01)

Glucagon-like peptide-1 receptor agonist use prior to spinal surgery results in reduced postoperative length of stay: A propensity-score matched analysis
by: Samuel N. Goldman, BS, et al.
Published: (2025-06-01)

Abnormal gut microbiota and impaired incretin effect as a cause of type 2 diabetes mellitus
by: T. Y. Demidova, et al.
Published: (2022-03-01)